Multidrug chemotherapy regimens are commonly used in the treatment of
cancer. The dose limiting tissue for chemotherapeutic treatment is oft
en the bone marrow, as many chemotherapeutic agents selectively target
rapidly proliferating cells. Bone marrow transplantation (BMT) has al
lowed an increase in chemotherapeutic dose; however, this type of ther
apy is associated with a prolonged suppression of immune function foll
owing the BMT. Although it may be possible to augment this immune func
tion, animal models which can be used to test various cytokines have n
ot been well described. We have developed a mouse model of multi-drug
chemotherapy which, like the human, demonstrates long term immune supp
ression following BMT. In this report, we describe the specific effect
s of this chemotherapy regimen on T cell differentiation in the thymus
of treated mice using three color FACS analysis. Results demonstrated
that specific populations of thymocytes are extremely susceptible to
chemotherapeutic insult. Both thymus cellularity and the immature CD3(
-)CD4(+)CD8(+) double positive population dropped to approximately 3%
of their original values by 7 days after chemotherapy initiation. Duri
ng the same time period, cells expressing both a beta and gamma beta T
cell receptors demonstrated a 2 - 6 fold increase in frequency. Simil
ar results were observed for the a beta(+)CD4(-)CD8(-) population of n
atural suppressor cells. Long-term changes in the proportion of cells
expressing the V beta 5 TCR were also observed following chemotherapy.
These results demonstrate that chemotherapy regimens may directly inf
luence T cell differentiation within the thymus, and also suggest that
long term changes in the T cell V beta repertoire may occur following
chemotherapy.